Immunovant
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $282,709,000.
Profit Margin
| 2019 | 0 | -28.59K | |
|---|---|---|---|
| 2020 | 0 | -66.38M | |
| 2021 | 0 | -107.43M | |
| 2022 | 0 | -156.73M | |
| 2023 | 0 | -210.96M | |
| 2024 | 0 | -259.33M |
IMVT Income Statement (2019 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 231K | 1.32M | 1.23M | 998K | 21K | 0 |
Gross profit | -231K | -1.32M | -1.23M | -998K | -21K | 0 |
Operating exp. | ||||||
Research and development | 212.92M | 160.25M | 101.80M | 68.60M | 47.92M | 25.73K |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 282.70M | 208.27M | 156.03M | 108.11M | 66.07M | 28.58K |
Operating income | -282.70M | -198.46M | -156.15M | -107.78M | -65.66M | -28.42K |
Other income (expenses), net | 23.94M | -2.67M | -655K | 328K | -2.51M | -155 |
Income before tax | -258.76M | -210.95M | -156.81M | -107.78M | -66.29M | -28.58K |
Income tax expense | 567K | 9K | -84K | -358K | 97K | 19 |
Net income | -259.33M | -210.96M | -156.73M | -107.43M | -66.38M | -28.59K |
Earnings per share | ||||||
Basic EPS | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -1.29 |
Diluted EPS | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -1.29 |
| Data source | Data source | Data source | Data source | Data source |